NASDAQ: RPHM - Reneo Pharmaceuticals, Inc.

Yield per half year: +20.53%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Reneo Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-04-08
ISIN US75974E1038
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://reneopharma.com
Цена ао 1.65
Change price per day: 0% (1.82)
Change price per week: 0% (1.82)
Change price per month: 0% (1.82)
Change price per 3 month: +9.64% (1.66)
Change price per half year: +20.53% (1.51)
Change price per year: +13.75% (1.6)
Change price per 3 year: -73.55% (6.88)
Change price per 5 year: 0% (1.82)
Change price per 10 year: 0% (1.82)
Change price per year to date: 0% (1.82)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.4847 10
P/E 0 0
EV/EBITDA -0.1973 0
Total: 3.75

Efficiency

Title Value Grade
ROA, % -72.03 0
ROE, % -87.34 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0118 10
Total: 9.2

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 433.98 10
Yield EPS, % 1476.7 10
Total: 8
More

Institutions Volume Share, %
NEA Management Company, LLC 4785494 14.32
Tang Capital Management, LLC 3330000 9.96
Carlyle Group Inc. 2698957 8.08
RiverVest Venture Management LLC 2534220 7.58
Octagon Capital Advisors LP 2250000 6.73
Bml Capital Management, LLC 1314229 3.93
Highbridge Capital Management, LLC. 1121704 3.36
Blackrock Inc. 983304 2.94
Vanguard Group Inc 978889 2.93
Aisling Capital Management LP 886075 2.65

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.00768 17.09 1.54048
Principal Healthcare Innovators ETF 0.00594 618.5 0.8416
Future Tech ETF 0.00594 426.34 0.8416
Invesco Nasdaq Biotechnology ETF 0.00486 28.58 0.8565
ProShares Ultra Nasdaq Biotechnology 0.00333 51.7 0.85651



Head Job title Payment Year of birth
Mr. Michael G. Grey Founder & Executive Chairman 100k 1953 (72 years)
Mr. Gregory J. Flesher President, CEO & Director 569.7k 1970 (55 years)
Mr. Michael P. Cruse Chief Operating Officer 535.47k 1972 (53 years)
Ms. Jennifer P. Lam SVP of Finance & Administration and Principal Financial & Accounting Officer N/A
Dr. Alejandro Dorenbaum M.D. Chief Medical Officer 466.23k 1961 (64 years)

Address: United States, Irvine. CA, 18575 Jamboree Road - open in Google maps, open in Yandex maps
Website: https://reneopharma.com